Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Evaluación clínica y genética de personas con trastornos no diagnosticados a través de la Red de enfermedades no diagnosticadas

2 de noviembre de 2026 actualizado por: National Human Genome Research Institute (NHGRI)

Evaluación clínica y genética de pacientes con enfermedades no diagnosticadas a través de la Red de Enfermedades No Diagnosticadas

Without an explanation for severe and sometimes life-threatening symptoms, patients and their families are left in a state of unknown. Many individuals find themselves being passed from physician to physician, undergoing countless and often repetitive tests in the hopes of finding answers and insight about what the future may hold. This long and arduous journey to find a diagnosis does not end for many patients- the Office of Rare Diseases Research (ORDR) notes that 6% of individuals seeking their assistance have an undiagnosed disorder. In 2008, the National Institutes of Health (NIH) Undiagnosed Diseases Program (UDP) was established with the goal of providing care and answers for these individuals with mysterious conditions who have long eluded diagnosis. The NIH UDP is a joint venture of the NIH ORDR, the National Human Genome Research Institute Intramural Research Program (NHGRI-IRP), and the NIH Clinical Research Center (CRC) (1-3). The goals of the NIH UDP are to: (1) provide answers for patients with undiagnosed diseases; (2) generate new knowledge about disease mechanisms; (3) assess the application of new approaches to phenotyping and the use of genomic technologies; and (4) identify potential therapeutic targets, if possible. To date, the UDP has evaluated 3300 medical records and admitted 750 individuals with rare and undiagnosed conditions to the NIH Clinical Center. The NIH UDP has identified more than 70 rare disease diagnoses and several new conditions. The success of the NIH UDP prompted the NIH Common Fund to support the establishment of a network of medical research centers, the Undiagnosed Diseases Network (UDN), for fiscal years 2013-2020. The clinical sites will perform extensive phenotyping, genetic analyses, and functional studies of potential disease-causing variants. The testing performed on patients involves medically indicated studies intended to help reach a diagnosis, as well as research investigations that include a skin biopsy, blood draws, and DNA analysis. In addition, the UDN will further the goals of the UDP by permitting the sharing of personally identifiable phenotypic and genotypic information within the network. By sharing participant information and encouraging collaboration, the UDN hopes to improve the understanding of rare conditions and advance the diagnostic process and care for individuals with undiagnosed diseases.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Descripción detallada

Without an explanation for severe and sometimes life-threatening symptoms, patients and their families are left in a state of unknown. Many individuals find themselves being passed from physician to physician, undergoing countless and often repetitive tests in the hopes of finding answers and insight about what the future may hold. This long and arduous journey to find a diagnosis does not end for many patients- the Office of Rare Diseases Research (ORDR) notes that 6% of individuals seeking their assistance have an undiagnosed disorder. In 2008, the National Institutes of Health (NIH) Undiagnosed Diseases Program (UDP) was established with the goal of providing care and answers for these individuals with mysterious conditions who have long eluded diagnosis. The NIH UDP is a joint venture of the NIH ORDR, the National Human Genome Research Institute Intramural Research Program (NHGRI-IRP), and the NIH Clinical Research Center (CRC) (1-3). The goals of the NIH UDP are to: (1) provide answers for patients with undiagnosed diseases; (2) generate new knowledge about disease mechanisms; (3) assess the application of new approaches to phenotyping and the use of genomic technologies; and (4) identify potential therapeutic targets, if possible.1-3 Prior to formation of the Undiagnosed Diseases Network (UDN), the UDP had evaluated 3300 medical records, admitted 750 individuals with rare and undiagnosed conditions to the NIH, and identified more than 70 rare disease diagnoses and several new conditions. The success of the NIH UDP prompted the NIH Common Fund to support the establishment of a network of medical research centers, the UDN, for fiscal years 2013-2022. The clinical sites perform extensive phenotyping, genetic analyses, and functional studies of potential disease-causing variants. The testing performed on patients involves medically indicated studies intended to help reach a diagnosis, as well as research investigations that include a skin biopsy, blood draws, and DNA analysis. In addition, the UDN is furthering the goals of the UDP by permitting the sharing of personally identifiable phenotypic and genotypic information within the network. By sharing participant information and encouraging collaboration, the UDN hopes to improve the understanding of rare conditions and advance the diagnostic process and care for individuals with undiagnosed diseases.

Tipo de estudio

De observación

Inscripción (Estimado)

20000

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Paul Mazur
  • Número de teléfono: (844) 746-4836
  • Correo electrónico: udn@hms.harvard.edu

Ubicaciones de estudio

    • Alabama
      • Birmingham, Alabama, Estados Unidos, 35233
        • Reclutamiento
        • University of Alabama at Birmingham
        • Contacto:
      • Huntsville, Alabama, Estados Unidos, 35806
        • Terminado
        • HudsonAlpha Institute for Biotechnology, Inc.
    • California
      • Los Angeles, California, Estados Unidos, 90095
        • Reclutamiento
        • University of California, Los Angeles
        • Contacto:
          • Stanley Nelson, M.D.
          • Número de teléfono: 310-794-7981
          • Correo electrónico: snelson@ucla.edu
      • Orange, California, Estados Unidos, 92668
        • Reclutamiento
        • University of California, Irvine Medical Center
        • Contacto:
          • Changrui Xiao, M.D.
          • Número de teléfono: 714-456-7720
          • Correo electrónico: changrx@hs.uci.edu
      • Stanford, California, Estados Unidos, 94305
        • Reclutamiento
        • Leland Stanford Junior University
        • Contacto:
          • Euan Ashley, MD, PhD
          • Número de teléfono: Not Listed
          • Correo electrónico: euan@stanford.edu
      • Stanford, California, Estados Unidos, 94305
        • Reclutamiento
        • Stanford Hospital and Clinics
        • Contacto:
      • Stanford, California, Estados Unidos, 94020
        • Terminado
        • Lucile Salter Packard Children's Hospital at Stanford
      • Stanford, California, Estados Unidos, 94305-5584
        • Reclutamiento
        • Stanford University
        • Contacto:
          • Euan Ashley, M.D.
          • Número de teléfono: 650-736-1147
          • Correo electrónico: euan@stanford.edu
    • District of Columbia
      • Washington D.C., District of Columbia, Estados Unidos, 20010
        • Reclutamiento
        • Childrens National Medical Center
        • Contacto:
    • Florida
      • Miami, Florida, Estados Unidos, 33136
        • Reclutamiento
        • University of Miami Miller School of Medicine
        • Contacto:
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60611
        • Aún no reclutando
        • Lurie Children s Hospital
        • Contacto:
    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46202-5262
        • Reclutamiento
        • Indiana University
        • Contacto:
          • Stephane Ware, M.D.
          • Número de teléfono: 317-274-8938
          • Correo electrónico: stware@iu.edu
    • Maryland
      • Bethesda, Maryland, Estados Unidos, 20892
        • Reclutamiento
        • National Institutes of Health Clinical Center
        • Contacto:
          • For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)
          • Número de teléfono: TTY dial 711 800-411-1222
          • Correo electrónico: ccopr@nih.gov
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02115
        • Reclutamiento
        • Brigham and Women's Hospital
        • Contacto:
      • Boston, Massachusetts, Estados Unidos, 02114
        • Reclutamiento
        • Massachusetts General Hospital
        • Contacto:
      • Boston, Massachusetts, Estados Unidos, 02115
      • Boston, Massachusetts, Estados Unidos, 02115
        • Aún no reclutando
        • Harvard U Faculty of Medicine
        • Contacto:
      • Boston, Massachusetts, Estados Unidos, 02115
        • Terminado
        • Harvard T.H. Chan School of Public Health
    • Minnesota
      • Rochester, Minnesota, Estados Unidos, 55905
    • Missouri
      • St Louis, Missouri, Estados Unidos, 63110
        • Reclutamiento
        • Washington University in St. Louis
        • Contacto:
          • Patricia Dickson
          • Número de teléfono: Not Listed
          • Correo electrónico: pdickson@wustl.edu
    • New York
      • New York, New York, Estados Unidos, 10013
        • Activo, no reclutando
        • New York Genome Center
    • North Carolina
      • Durham, North Carolina, Estados Unidos, 27710
        • Reclutamiento
        • Duke University Health System
        • Contacto:
    • Oregon
      • Eugene, Oregon, Estados Unidos, 97403
        • Aún no reclutando
        • University of Oregon
        • Contacto:
      • Portland, Oregon, Estados Unidos, 97201-3098
        • Terminado
        • Oregon Health Sciences University
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19104
        • Reclutamiento
        • Children's Hospital of Philadelphia
        • Contacto:
      • Philadelphia, Pennsylvania, Estados Unidos, 19104-6056
    • Tennessee
      • Nashville, Tennessee, Estados Unidos, 37232
        • Reclutamiento
        • Vanderbilt University Medical Center
        • Contacto:
    • Texas
      • Houston, Texas, Estados Unidos, 77030
        • Reclutamiento
        • Baylor College of Medicine
        • Contacto:
          • Brendan Lee, M.D.
          • Número de teléfono: 713-798-8835
          • Correo electrónico: blee@bcm.edu
    • Utah
      • Salt Lake City, Utah, Estados Unidos, 84112
        • Reclutamiento
        • University of Utah
        • Contacto:
    • Washington
      • Richland, Washington, Estados Unidos, 99354
        • Terminado
        • Pacific Northwest National Laboratory
      • Seattle, Washington, Estados Unidos, 98195
        • Reclutamiento
        • University of Washington
        • Contacto:
          • Gail Jarvik, M.D.
          • Número de teléfono: Not Listed
          • Correo electrónico: pair@uw.edu
      • Seattle, Washington, Estados Unidos, 98101
    • Wisconsin
      • Milwaukee, Wisconsin, Estados Unidos, 53226
        • Reclutamiento
        • Medical College of Wisconsin

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

1 mes a 100 años (Niño, Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

Individuals with undiagnosed conditions

Descripción

  • INCLUSION CRITERIA:

Ideal participants for tier 2-4 evaluations include individuals with:

  • One or more objective findings pertinent to the phenotype for which a case was submitted.
  • No diagnosis despite evaluation by specialists who assessed the patient for the objective finding(s).
  • Agreement for the storage and sharing of information and biomaterials, in an identified fashion amongst the UDN centers, and in a de-identified fashion to research sites beyond the network.

Participants unable to consent can be enrolled.

EXCLUSION CRITERIA:

Individuals who are unlikely to be assigned to tier 2-4 evaluations include those with:

  • Reported symptoms with no relevant objective findings.
  • A diagnosis explaining objective findings.
  • A diagnosis suggested on record review.
  • Unwillingness to share data.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: CASE_ONLY
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Undiagnosed disorders

Patients with rare, undiagnosed disorders.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Create an integrated and collaborative research community across multiple clinical sites and between laboratory and clinical investigators prepared to investigate the pathophysiology of these new and rare diseases, the impact of the diagnostic p...
Periodo de tiempo: Day 1-5 and followup

Create an integrated and collaborative research community across multiple clinical sites and between laboratory and clinical investigators prepared to investigate the pathophysiology of these new and rare diseases, the impact of the diagnostic process on patients and families, and share this understanding to identify improved options for optimal patient management.

Day 1-5 and followup
Facilitate research into the etiology of undiagnosed diseases, by collecting and sharing standardized, high-quality clinical and laboratory data including genotyping, phenotyping, and documentation of environmental exposures
Periodo de tiempo: Day 1-5 and followup

Facilitate research into the etiology of undiagnosed diseases, by collecting and sharing standardized, high-quality clinical and laboratory data including genotyping, phenotyping, and documentation of environmental exposures.

Day 1-5 and followup
Improve the level of diagnosis and care for patients with undiagnosed diseases through the development of common and site-specific protocols designed by an enlarged community of investigators
Periodo de tiempo: Day 1-5 and followup

Improve the level of diagnosis and care for patients with undiagnosed diseases through the development of common and site-specific protocols designed by an enlarged community of investigators.

Day 1-5 and followup

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: William A Gahl, M.D., National Human Genome Research Institute (NHGRI)

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

16 de septiembre de 2015

Finalización primaria (Estimado)

16 de septiembre de 2099

Finalización del estudio (Estimado)

31 de diciembre de 2099

Fechas de registro del estudio

Enviado por primera vez

19 de mayo de 2015

Primero enviado que cumplió con los criterios de control de calidad

19 de mayo de 2015

Publicado por primera vez (Estimado)

21 de mayo de 2015

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

3 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

2 de noviembre de 2026

Última verificación

28 de octubre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 150130
  • 15-HG-0130

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .